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Abstract
Gestational diabetes mellitus (GDM) is a serious problem growing worldwide that needs to be addressed with urgency in consideration of the
resulting severe complications for both mother and fetus. Growing evidence indicates that a healthy diet rich in fruit, vegetables, nuts,
extra-virgin olive oil and fish has beneficial effects in both the prevention and management of several human diseases and metabolic
disorders. In this review, we discuss the latest data concerning the effects of dietary bioactive compounds such as polyphenols and
PUFA on the molecular mechanisms regulating glucose homoeostasis. Several studies, mostly based on in vitro and animal models, indicate
that dietary polyphenols, mainly flavonoids, positively modulate the insulin signalling pathway by attenuating hyperglycaemia
and insulin resistance, reducing inflammatory adipokines, and modifying microRNA (miRNA) profiles. Very few data about the influence
of dietary exposure on GDM outcomes are available, although this approach deserves careful consideration. Further investigation,
which includes exploring the ‘omics’ world, is needed to better understand the complex interaction between dietary compounds
and GDM.
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Gestational diabetes mellitus (GDM) is the most common
metabolic disorder during pregnancy(1), and its prevalence is
increasing worldwide(2). Women with GDM are at a high risk of
developing type 2 diabetes (T2D) later in life(1); in addition, the
higher baseline BMI and weight gain often found after GDM
occurrence increase the risk of progression from GDM to
T2D(3). Moreover, uncontrolled GDM is associated with a
detrimental intra-uterine environment, which leads to fetal
complications and an increased risk for the child of developing
obesity and metabolic disorders(4,5).
In response to the marked rise in GDM, it is of paramount
importance to identify appropriate treatments to prevent
maternal and fetal complications associated with this disease.
At present, the management of GDM is a big challenge
because of its heterogeneity (i.e. ethnic as well as intra-, and
inter-country differences)(2,6,7), and the incomplete knowledge
of its pathophysiology(8). As a result, standardised guidelines for
GDM are difficult to arrive at worldwide, as are the intervention
strategies aimed at preventing or/and reducing the burden of
this disorder. In addition, obesity and maternal overweight have
been considered as the main risk factors for GDM(1); the
reduction of these risk factors is essential for the well-being of
mother and offspring(5).
Pre-pregnancy and early pregnancy are the best periods for a
dietary intervention to control weight in order to prevent the
long-lasting effects of maternal diabetes or obesity(9).
There is increasing evidence that the dietary patterns having
beneficial effects both in prevention and management of dia-
betes are characterised by high consumption of plant foods (e.g.
whole grains, fruit, vegetables and extra-virgin olive oil, nuts)
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and fish, and low consumption of animal-based, high-fat, pro-
cessed foods, that is, the Mediterranean-style diet (MedDiet)(10).
The MedDiet is a primarily plant-based dietary pattern that has
been strongly associated with lower incidence of CVD, and
neoplastic diseases, and an overall reduced mortality(11,12).
Adherence to the MedDiet correlates with better glycaemic
control, a reduced risk of both total and cardiovascular mortality
in diabetic subjects in Mediterranean populations(13–15) and a
lower risk of metabolic syndrome and CVD in non-
Mediterranean populations(16–19). These findings indicate that
the adoption of the MedDiet model by populations having dif-
ferent dietary habits is effective in reducing the risk of non-
communicable disorders.
The short-term – 4 weeks – consumption of a DASH diet
(Dietary Approaches to Stop Hypertension), rich in fruits,
vegetables, whole grains and lower amounts of SFA, improved
pregnancy outcomes among GDM women(20). Pre-pregnancy
adherence to healthy dietary patterns(21) and the MedDiet is
associated with lower incidence of GDM and a better degree of
glucose tolerance in no-GDM pregnant women(22).
In any case, the mechanisms underlying the protective
effects of the MedDiet are not clear as yet. The high
MUFA:SFA ratio, the increased level of PUFA, the low content
of trans-fatty acids (FA) and the high content of fibres, vitamins,
mineral salts and phytochemicals compounds may contribute to
the beneficial effects of MedDiet(23–25). Over the past years,
researchers have focused their attention on the role of plant-
derived, functional foods and their bioactive compounds in
the control of various aspects of diabetes mellitus(26,27). Among
the known natural bioactive components, polyphenols have
been shown to have anti-hyperglycaemic effects, antioxidant
and anti-inflammatory activities and no side effects(27–29). In
addition, the increasing demand of non-fish source of n-3 PUFA
is worth considering, in view of the beneficial effects of these
FA in GDM women(24), and during pregnancy in general, not to
mention the worldwide increase in the number of vegetarians
and vegans(30).
The knowledge of how (i.e. molecular mechanisms) and
where (i.e. targets) a given biocompound acts is of crucial
importance to better understand the mechanisms governing the
dietary impact on the metabolic system in GDM.
We found a good number of articles in English published up
to August 2015 by searching in PubMed, using the key words
‘gestational diabetes mellitus’, ‘diabetes’, ‘insulin resistance’,
‘hyperglycaemia’, ‘adipokines’, ‘inflammation’, ‘microRNAs’,
‘PUFAs’, molecular mechanisms’; these key words were sear-
ched in combination with the key words ‘Mediterranean diet’,
vegetables food’, ‘polyphenols’, ‘phytochemicals’, ‘bioactive
compounds’. Data regarding the association between plant-
derived compounds and GDM are scarce. This review discusses
the current knowledge and issue about the impact of dietary
polyphenols on the mechanisms and/or factors regulating glu-
cose homoeostasis, inflammation and adipose tissue (AT)
function in metabolic alterations associated with GDM. The role
of n-3 FA in pregnancy is also addressed. From all these data,
MedDiet bioactive compounds appear to be more and more
useful players to be included in future research approaches
designed to prevent and treat GDM.
Dietary polyphenols
The MedDiet is characterised by a high intake of vegetable
food(31), and polyphenols are the biggest class of plant-derived
bioactive compounds(32–34). These phytochemicals are found in
quite variable quantities in fruit, vegetables, cereals, nuts, tea,
wine, chocolate, olives, extra-virgin olive oil and plant-derived
foodstuffs, as well as spices and algae(34–36). Even more data
link polyphenol intake with both health promotion and the
prevention of non-communicable diseases such as CVD, stroke,
T2D and some cancers(27–29,37). Polyphenols are a complex
class of compounds having a phenolic ring in their structure;
they can be classified on the basis of the numbers of phenol
rings they contain and the structural elements that bind these
rings(32,35). The majority of polyphenols exist as glycosides,
esters, polymers and in hydroxylated form(35,37). They are
extensively modified throughout stomach, small intestine, colon
and liver(38); thus, a single polyphenol can generate several
active metabolites(39). Because of their chemical structures,
dietary polyphenols exert multiple activities by interacting with
several molecular pathways and cellular components including
microRNA (miRNA)(28,37,40,41). The main classes of polyphenols
are flavonoids, phenolic acids, stilbenes and lignans(32,35). Fla-
vonoids are the most abundant class of polyphenols in our diet
and include different subclasses, that is, flavonols, flavones,
flavanols, flavanones, anthocyanidins and isoflavones(42,43)
(Fig. 1). The evaluation of the actual contribution of dietary
polyphenols to human health is challenging, as several factors
come into play: food-related factors (i.e. amount consumed, food
content and bioavailability) and host-related factors (i.e. genetics,
obesity, pregnancy and gut microbiota)(44). Moreover, chemical
structure, synergistic effects among different polyphenols and
interaction with cellular components (e.g. membrane, proteins,
enzymes, receptors and transcription factors) render the evaluation
quite hard(44,45). An accurate measurement of the exposure to
specific compounds will make it possible to associate these factors
with health status and disease outcomes. To this end, efforts have
been made to assess the following: (i) the level of adherence to the
MedDiet, by the Mediterranean Dietary Serving Score, which
accounts for the consumption of foods and food groups per meal,
day or week(46); (ii) the content of polyphenols in food and their
metabolism(34), as well as the human intake of total and specific
polyphenols, by the creation of online database (e.g. Phenol-
Explorer and United States Department of Agriculture data-
base)(34,42,43,47–49); and (iii) novel biomarkers for polyphenol
ingestion in biological fluids, by measuring food metabolome(50–52).
Glucose homoeostasis regulation
GDM is defined as carbohydrate intolerance during preg-
nancy(1). Pregnancy is characterised by a complex process of
endocrine-metabolic changes, including physiological insulin
resistance (IR), necessary to ensure the supply of nutrients to
the fetus and to adequately prepare the maternal organism for
childbirth and lactation(53). GDM develops when the pregnant
woman is not able to produce an adequate insulin response to
compensate for physiological IR(54). IR during pregnancy is
uniquely associated with a decrease in insulin receptor sub-
strate 1 (IRS-1) tyrosine phosphorylation, primarily because of a
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decreased expression of IRS-1 protein(55). Nevertheless, in GDM
subjects, there is an additional decrease in tyrosine phosphor-
ylation of the insulin receptor β subunit, associated with further
decreases in glucose transport activity(55,56). Lower levels of
tyrosine kinase receptor activity (30–40%), IRS-1 expression
and activation, and GLUT4, in fact, have been detected in
pregnancy with respect to pre-pregnancy status(55,56). Specifi-
cally, IRS-1 tyrosine phosphorylation has been found to be
significantly reduced in muscle from pregnant control and
obese GDM subjects, as reflected by a 23 and 44% reduction,
respectively, compared with non-pregnant women(57). AT,
through a large arrays of secreted factors, participates in the
induction and regulation of IR both in non-pregnant and
pregnant subjects(58). Maternal pre-pregnancy obesity decrea-
ses insulin sensitivity and positively associates with the risk of
GDM(59). A recent study has shown that AT inflammasome
(caspase-1 and IL-1β) is involved in the development of IR in
GDM-complicated pregnancies(60). Increased IL-1β expression
has been observed in AT from GDM women; incubation of AT
with IL-1β results in a significant attenuation of phosphorylated
IRS-1 protein expression, GLUT4 mRNA and protein expression
and glucose uptake, indicating the importance of inflamma-
some in the pathophysiology of GDM(60).
Over the past years, the role of miRNA in gene regulation has
been gaining attention; miRNA are implicated in regulating
cholesterol biosynthesis, carbohydrate and lipid metabolism(61),
as well as in insulin production, secretion and action(62) (i.e. in
glucose homoeostasis)(62–65), by interacting with specific mRNA
targets(66). Accordingly, miRNA have been explored in GDM
with the aim of using them as early biomarkers of disease(67–70),
as they are present in the blood or other biological fluids(67,71).
To date, few investigations have been performed; two studies
conducted in China have found decreased levels of
miR-29a, -132 -and -222(69), and increased levels of miR-16-5p,
miR-17-5p, miR-19a-3p, miR-19b-3p and miR-20a-5p, in gesta-
tional weeks 16–19 in the serum of pregnant women who later
developed GDM in gestational weeks 25–28, with respect to
women who did not develop GDM(70). However, hypergly-
cemic non-pregnant rodents have shown opposite expression
of mir-29 and mir-132 families. MiR-29 family is involved in the
insulin-signalling pathway; muscle, fat and liver from hyper-
glycaemic Goto–Kakizaki rats exhibit up-regulation of miR-29a
and miR-29b(72). High glucose induces the up-regulation of
miR29a associated(72) with the decrease in IRS-1, downstream
kinase Akt and glycogen synthase kinase 3β, (GSK3β) proteins,
in both rat myocytes(73) and human pancreatic β-cells(74).
Polyphenols
Flavonols
Quercetin
Dark chocolate
25 mg/100 ml;
buckwheat
flour,11 mg/100 g; 
orange juice
1.06 mg/100 ml;
capers 32 mg/100g;
onion 2 mg/100g
Isoflavones
Daidzein
Soya and soya 
products
0.58–13.60 
mg/100 ml;
common bean 
0.80 mg/100g
Genistein
Soya and soya products
0.12–10 mg/100 ml; 
common bean 0.60 mg/100 g
Anthocyanins
Cyanidin-3-glucoside
Blackberry 138.72 mg/100 g;
pomegranate juice 3.43 mg/100 ml Epigallocatechin gallate
Tea infusions 0.78–17.89 mg/100 ml; 
hazelnut raw 1.10 mg/g
Flavanols Flavanones
Narinign
Grapefruit juice 37.76 mg/ml; 
rosemary fresh 55.05 mg/g
Naringenin
Grapefruit juice 
1.56 mg/100ml; 
oregano dried 
372 mg/100g
Hesperidin
Orange juice 52.68 mg/100 ml;
lemon juice 24.99 mg/100 ml;
peppermint dried 480.65 mg/100 ml
Curcuminoids
Curcumin
Turmeric dried 
2213.57 mg/100 g;
curry powder 
285.26 mg/100 g
Tyrosol
Olive black raw 
72.02 mg/100 g; 
extra-virgin olive 
oil 14.4 mg/100 ml; 
vinegar 3 mg/100ml
Hydroxytyrosol
Olive black raw 
65.93 mg/100 g
extra-virgin olive 
oil 0.77 mg/100 ml;
wine 
0.53 mg/100 ml
Oleuropein
Olive black raw 
72.02 mg/100 g; 
extra-virgin
olive oil 
0.17 mg/100 ml
Fisetin
Strawberry 160 µg/g; 
apple 26.9 µg/g;
onion 4.8 µg/g
Flavonoids
Stilbenes
Resveratrol
Red wine 
3.02 mg/100 ml; 
cranberry 
1.92 mg/g
Protocatechuic acid
Cereals 0.04–
2.55 mg/100 g; 
date dried 4.94 mg/100 g; 
almond 0.26 mg/100 g; 
chicory 16.78–21.79 mg/g; 
onion 2 mg/100 g
Caffeic acid
Dried sage 26.40 mg/7100g; 
fresh oregano 10.40 mg/g; 
sunflower seed 
8.17 mg/100 g;
chicory 2.6 1 mg/100 g; 
eggplant 0.38 mg/100 g
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Fig. 1. Chemical structure and main dietary source of polyphenols discussed in this review regarding their capability to modulate glucose metabolism signalling.
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MiR-132 expression is up-regulated in pancreatic islets of
pre-diabetic (6 weeks old) and diabetic db/db mice
(14–20 weeks)(75); this increase improved glucose-stimulated
insulin release and increased cell proliferation, which suggests
that the modification of miR-132 levels might contribute to
compensatory β-cell mass expansion elicited in response to
IR(75). In GDM women, the up-regulation of miR-222 has been
found to be associated with reduced protein levels of both
oestrogen receptor (ER)-α and GLUT4 in omental AT, obtained
at the time of caesarean delivery, and with increased serum
estradiol levels(76). In consideration of these findings, we may
assume that miRNA are expressed in a species-, tissue-specific
and time-dependent manner.
Furthermore, miRNA profiles of peripheral blood mono-
nuclear cells isolated from Brazilian GDM women, obtained by
using microarray platforms, have identified ten miRNA that
seemed to be specific for GDM, namely, miR-101, miR-1180,
miR-1268, miR-181a, miR-181d, miR-26a, miR-29a, miR-29c,
miR-30b and miR-595(67).The target genes of most of these
miRNA are involved in insulin signalling, angiogenesis, IR and
AT dysfunction(66). It is noteworthy that miR-181a is increased in
the serum of diabetic patients, as well as in IR cultured
hepatocytes and liver(77). Inhibition of miR-181a by antisense
oligonucleotides restores insulin sensitivity in hepatocytes, thus
providing evidence of a potential therapeutic strategy for treating
IR and T2D(77). On the other hand, miR-30 belonging to the
miR-30 family that has a key role in angiogenesis(78) might be
involved in the hyper capillarisation of the placenta in women
with mild hyperglycaemia(79,80). Furthermore, miR-30 family
members increase in abundance during the differentiation of
pancreatic islet-derived mesenchymal cells into hormone-
producing islet-like cell aggregates, thus indicating their partici-
pation in the regulatory signalling of the embryonic development
of human pancreatic islets(81). However, the miRNA modifica-
tions so far observed in GDM women result from a limited
number of screened subjects (from six to twenty). In addition,
people from different countries appear to have different miRNA
profiles, except for miR-29, in the same metabolic condition. In
conclusion, although the above data provide evidence that
miRNA are promising, non-invasive biomarkers of GDM, further
research with larger cohorts is warranted.
Polyphenols effects
The maintenance of glucose homoeostasis is extremely impor-
tant for human physiology(82). Growing evidence indicates that
polyphenols, contained in fruits and vegetables, might influence
glucose homoeostasis by several mechanisms such as by
(i) inhibiting carbohydrate digestion and glucose absorption in
the intestine, (ii) stimulating insulin secretion from pancreatic
β-cells, (iii) modulating glucose release from liver and (iv) acti-
vating insulin receptors and glucose uptake in insulin-sensitive
tissues(83). The bioactive food components can modify gene
expression and regulate different signalling pathways, thus
affecting muscle, liver, pancreatic β-cells, hypothalamus and AT
functions, thereby regulating glucose homoeostasis(84,85). This
regulatory activity occurs also by modulating miRNA gene
expression(40,86–89) (Fig. 2). Isoflavones, anthocyanins, flavanols
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Fig. 2. Crosstalk among signalling pathways in regulating glucose metabolism. All of the factors that appear in this scheme are potential points of action of
polyphenols. , Activation; , inhibition; , modulation; JAK/STAT, Janus kinase/signal transducer and activator of transcription; AMPK, AMP-activated
protein kinase; JNK, c-Jun N-terminal kinase; IRS1/2, insulin receptor substrate 1/2; MAPK, mitogen-activated protein kinases; PDK1, 3-phosphoinositide-dependent
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and catechins appear to enhance β-cell function and glucose
tolerance in animal models and humans and to protect against
diabetes(29). Genistein and daidzein are the major dietary
isoflavones present primarily in soya foods(90). Long-term gen-
istein exposure (1–10 µM for 48 h) improved glucose-stimulated
insulin secretion (GSIS) in mouse and human pancreatic islets(91);
this effect appears to be mediated by cyclic AMP/protein
kinase A signalling activation and increased intracellular Ca2+
levels(91) (Table 1).
The flavanol epigallocatechin gallate (EGCG), a main com-
ponent of green tea extract, preserves the insulin secretory
machinery; EGCG (10 µM for 48 h) stimulates the activation
of the IRS-2 signalling in rat insulinoma pancreatic β-cells
(RIN-m5F), also under chronic hyperglycaemia(92). EGCG
increases the activity of AMP-activated protein kinase (AMPK)
through Thr172 phosphorylation, further strengthening the
hypothesis that AMPK is involved in counteracting the glucoli-
potoxicity induced by high-glucose condition(92). AMPK is an
energy-sensing enzyme recognised as a master regulator of
whole-body energy homoeostasis; its activation increases
GLUT4 expression and membrane translocation in skeletal
muscle, thereby improving glucose uptake(93). In this regard,
AMPK has been considered as one of the targets of the insulin-
sensitising drugs metformin and thiazolidinediones(93).
EGCG (20, 40μM for 24h) improved the insulin-stimulated
glucose uptake also in dexamethasone-treated skeletal muscle
cells L6, associated with an increased AMPK phosphorylation
and GLUT4 membrane translocation(94). Furthermore, the
dexamethasone-stimulated inactivation of IRS-1 because of
increased Ser307 phosphorylation has been significantly reversed
by EGCG treatment(94). Results from the miRNA profiling suggest
that EGCG may exert its biological functions through up- or
down-regulating multiple miRNA as well(95). In particular, EGCG
(50mg/l for 5 h), grape seed (100mg/l for 5 h) and cocoa
proanthocyanidin extracts (100mg/l for 5 h) down-regulated
miR-30b expression in human hepatocellular carcinoma HepG2
cells(78). A longer EGCG (100μM for 24h) treatment reduced
miR-181d and miR-222 expression as well, in HepG2 cells(95).
Anthocyanins are widely distributed in the human diet
through berries, fruits, vegetables and red wine(96). Pretreat-
ment with bayberry fruit extracts (0·5 μmol/l cyanidin-3-
glucoside (C3G) for 12 h) up-regulated pancreatic duodenal
homeobox-1 gene expression, which is associated with
increased levels of insulin-like growth factor-II gene transcript
and insulin, in rat insulinoma cell line INS-1β-cells(97).
We have shown that C3G (10·50 µM for 18 h) and its meta-
bolite protocatechuic acid (PCA; 100 µM for 18 h) increased
glucose uptake and GLUT4 membrane translocation in murine
adipocytes and visceral human adipocytes(98–100). Specifically,
PCA appeared to exert insulin-like effects by stimulating IRS-1
tyrosine phosphorylation and Akt activation(98–100).
Caffeic acid, naringenin and quercetin (10 − 6 µM for 72 h
each), present in many plants, enhance GSIS and glucose
sensitivity in rat pancreatic INS-1E cells(101). These compounds
differently modulate gene expression profiles to improve β-cell
survival and function during glucotoxicity (e.g. naringenin and
quercetin up-regulated GLUT2, glucokinase, AKT1, whereas
caffeic acid increased AKT2 and all the three compounds
increased INS-1, mRNA expression)(101). Similarly, curcumin
(5–15 µM for 24 h), a yellow pigment isolated from Curcuma
Longa, increases insulin gene expression and GSIS in a
dose-dependent manner in INS-1 cells(102). In doing so, curcu-
min up-regulates the expression of GLUT2, the phosphorylation
of IRS-1, phosphatidylinositol-3-kinase (PI3K) and Akt, sug-
gesting that curcumin prevents the high-glucose-induced
reduction of insulin expression and secretion by activating the
PI3K/Akt/GLUT2 pathway in INS-1 cells(102). Curcumin treat-
ment modulates the expression profile of several miRNA,
including up-regulation of miRNA-26a in A549 human lung
adenocarcinoma cell line (curcumin: 15 µM for 48 h)(103) and
miR-181a in BxPC-3 human pancreatic carcinoma cell line
(curcumin: 10 µM for 72 h)(104).
Consistent with in vitro studies, animal intervention studies
showed that supplementation with genistein (0·2 g/kg diet) or
daidzein (0·2 g/kg diet) for 9 weeks preserved β-cells and
reduced blood glucose levels by inducing insulin secretion, in
non-obese diabetic mice(105). Similarly, administration of 0·1ml
of bayberry fruit extracts (containing 150 μg of C3G)/10 g of
body weight twice per day for 30 d significantly reduced blood
glucose and improved glucose tolerance in streptozotocin-
induced diabetic mice(97).
Changes in the expression of a large number of different
miRNA have been observed after each polyphenol supple-
mentation(88). MiRNA profile expression was evaluated in the
livers of wild-type (C57B6/J) mice or apoE–/– mice fed diets
supplemented with different polyphenols (including quercetin,
hesperidin, naringenin, proanthocyanidin, caffeic acid, curcu-
min)(88,106). MiR-29a and miR-30b expression were down-
regulated by almost all the tested polyphenols; miR-222 was
down-regulated by caffeic acid (300mg/d for 2 weeks) and
hesperidin (30mg/d for 2 weeks); miR-181a was down-regulated
by curcumin (30mg/d for 2 weeks) and hesperidin and
up-regulated by naringin (30mg/d for 2 weeks), quercetin
(30mg/d for 2 weeks) and proanthocyanidin (300mg/d for
2 weeks); miR-132 was up-regulated by naringin(88). This study
highlights the importance of miRNA as modulators of dietary
polyphenols activities, in vivo(88).
Human intervention trials and cohort studies have reported
that dietary supplementation with 22·5 g of whole blueberry
twice daily (1462mg of total phenolics, 668mg of anthocyanins)
for 6 weeks resulted in blood glucose concentration reduction
and in insulin sensitivity improvement in obese, non-diabetic,
IR subjects(107). Data from three prospective cohort studies
involving 200 000 US men and women showed that a higher
consumption of anthocyanin-rich fruit is associated with a lower
risk of T2D(108). Collectively, anthocyanins and its glycosides,
alone or in combination, improve glucose homoeostasis by
influencing β-cell mass and function, insulin sensitivity, glucose
uptake and insulin signalling(85).
There is no doubt that dietary polyphenols have beneficial
effects on β-cell function and glucose homoeostasis taking into
account that most of them are capable of modulating almost all
the players, including several miRNA, in the glucose uptake
machinery. Although promising data have been obtained so far,
no information on the effects of these bioactive compounds in
GDM setting are available as yet.
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Adipokines and gestational diabetes
It is well known that adipocyte-derived cytokines (adipokines)
are involved in the modulation of a wide range of physiological
processes including lipid metabolism, atherosclerosis,
angiogenesis and insulin sensitivity(109,110). The human
gestational tissues, as well as AT, produce and release a large
array of pro-inflammatory cytokines; the activation of some
inflammatory pathways is necessary to induce maternal IR,
which is required for the progression of normal gesta-
tion(9,111,112). GDM associates with the amplification of the
low-grade inflammation already existing in normal preg-
nancy(113,114). Indeed, serum TNFα, IL-1β and IL-6 levels are
higher in GDM women as compared with control pregnant
women(115). Notably, pre-pregnant obesity in GMD women
worsens this inflammatory picture by up-regulating TNFα, IL-1β
and/or leptin, and by down-regulating genes involved in AT
lipid metabolism such as PPARα, PPARδ, PPARγ, retinoid X
receptor-α (RXRα) and sterol regulatory element-binding
protein-1c (SREBP1c), in AT(109).
Over the past years, various adipokines such as adiponectin
and leptin have been shown to play a role in normal pregnancy,
as well as in complications of pregnancy including
GDM(9,110,116,117). Low adiponectin serum levels appear to be
linked with T2D and IR(118). A study conducted on 445 pregnant
women demonstrated that lower levels of adiponectin during the
first trimester of pregnancy are associated with increased risk of
developing GDM during the second trimester, independently of
other early pregnancy major risk factors(119). Further, a nested
case–control study showed that lower adiponectin levels
measured 6 years before pregnancy were associated with a
5-fold increased risk of developing GDM(120). Thus, an early low
adiponectin expression, which most likely reflects pre-existing
IR, could be considered a useful biomarker to identify women at
high risk for GDM and allow for early therapeutic interven-
tions(120). Adiponectin acts as an insulin-sensitising agent, and its
action is complex and incompletely defined, but the collected
evidence suggests that, by binding with its receptors, adiponectin
activates three key signalling pathways in muscle and liver:
AMPK, p38 mitogen-activated protein kinase (p38 MAPK) and
PPAR(121). The activation of these pathways results in FA
oxidation (FAO) and glucose uptake in skeletal muscle, and in
the inhibition of gluconeogenesis in the liver(121). Reduced
adiponectin could be held accountable for the lower FAO
observed in placentas of GDM women compared with the
control group(122). Adiponectin gene expression, processing and
secretion is up-regulated by PPARγ agonist; PPARγ activation
results in increased insulin sensitivity, in skeletal muscle and
liver, by inducing the release of insulin-sensitising adipokines
including adiponectin(123). Administration of adiponectin to dia-
betic mice(124) and obese pregnant mice enhances insulin
activity(125), prevents fetal overgrowth(125), normalises placental
insulin/mammalian target of rapamycin complex 1 (mTORC1),
PPARα signalling and placental nutrient transport(125). Adipo-
nectin also mediates the crosstalk between AT and the vessel
wall; thus, in virtue of its pleiotropic activities on multiple targets,
it seems to have a protective role against vascular dysfunction
induced by obesity and diabetes(126).
TNFα and leptin have been suggested as the strongest pre-
dictors of pregnancy-related IR(127,128). Hyperleptinaemia in
early pregnancy (13 weeks) appears to be a good predictor of
GDM risk, independent of maternal adiposity(129,130). In week
30 of pregnancy, leptin levels have been found to be similar in
both GDM and no-GDM subjects, but they remained elevated
after delivery in the GDM group(131).
Recent systematic reviews have highlighted higher and lower
levels of plasma leptin and adiponectin, respectively, in the first
or second trimester of pregnancy(132), and this condition per-
sisted, associated also with high TNF-α levels, in the late second
or third trimester of pregnancy(133), in GDM patients compared
with normal pregnancies. These findings corroborate the role
exerted by the altered balance pro-inflammatory/anti-inflam-
matory factors in the impaired glucose homoeostasis in GDM.
Increased levels of leptin have been found in visceral AT of
obese and GDM women(109). Leptin, predominantly produced
by adipocytes, is considered an essential factor in maintaining
energy homoeostasis, as it regulates food intake and energy
expenditure via specific receptors in the hypothalamus(134).
Leptin acts by activating Janus kinase/signal transducer and
activator of transcription signalling, although other important
intracellular signalling including PI3K, AMPK and MAPK appear
to be involved as well(134).
In GDM women, TNFα and leptin levels are elevated; the
increased TNFα expression causes a chronic inflammatory
environment with enhanced leptin production, which, in turn,
increases TNFα and IL-6 production by monocytes(135), gen-
erating a vicious circle that amplifies the inflammatory situation
and worsens the metabolic dysfunction in GDM. Although the
significance of leptin and adiponectin is relatively well char-
acterised as for their effects on glucose and lipid metabolism in
diabetes, the molecular mechanisms by which these adipokines
exert their effects on insulin action are not completely defined.
Much more research is needed especially in the light of the
growing list of molecules identified as adipokines, for example,
visfatin, apelin, retinol-binding protein 4, vaspin, omentin and
adiposity FA-binding protein 4 (FABP4), which renders the
comprehension of the existing network and the interactions
among them more complicated (9,136,137).
Polyphenols effects
The beneficial effects of MedDiet dietary compounds on diabetes
are associated with reduced biomarkers of inflammation(138–140).
Taking into account the importance of the insulin-sensitising
effects of adiponectin, enhancing adiponectin/AdipoR function
may be an interesting therapeutic strategy against IR(141). Diet-
ary compounds such as fish oil, linoleic acid (LA), seed extract,
green tea extract and resveratrol (RSV) elevated adiponectin
concentration; specifically, RSV (50 µM for 24 h) treatment sti-
mulated adiponectin expression and reduced mRNA levels of
leptin in 3T3-L1 adipocytes(142,143). The stimulatory effect of
RSV has been shown to be mediated via histone deacetylase
sirtuin 1 (Sirt-1)-independent mechanism and is mainly because
of phosphoinositide-dependent protein kinase-1/Akt signalling
pathway suppression, in the activation of the transcription fac-
tor forkhead box O-1 (FOXO1), and the AMPK signalling
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pathway(142). RSV (0·1–10 μM) reduced the expression and
release of IL-6 and TNFα in RAW 264.7 macrophages and
3T3-L1 cells, in association with a reduced extracellular
signal-regulated protein kinases 1/2 (ERK1/2) and NF-κB acti-
vation(144). The high-glucose-induced nitric oxide (NO) reduc-
tion was reverted by RSV (0·1–10 μM for 24 h) incubation in
bovine artery endothelial cells, because of enhanced endothe-
lial NO synthase mRNA and activity(145). Altogether, these
findings strongly indicate that RSV could be a therapeutic
supplement to counteract the diabetic condition.
C3G treatment (12·5, 25, 50 µM for 24 h) induced adiponectin
expression in 3T3-L1 and human adipocytes(98,146). As regards
the molecular mechanisms, C3G induced FOXO1 deacetylation
and transcriptional activity, as well as increased PPARγ activ-
ity(98), which, in turn, brought about adiponectin expression
and secretion, in adipocytes(146). In addition, flavonoid fisetin
(0·1–10 μM for 24 h) increased adiponectin gene transcription by
inducing SIRT-1-deacetylase activity and PPAR activation, in
mouse adipocytes(147,148).
Virgin olive oil components such as hydroxytyrosol
(HT; 0·1–20 μM for 1 h pretreatment) and oleic acid (100 μM for
48 h pretreatment) alone or in combination in human adipo-
cytes can prevent TNFα-induced down-regulation of
adiponectin by attenuating PPARγ suppression mediated by
c-Jun N-terminal kinase (JNK)(149). Moreover, HT, oleuropein,
taxifolin and tyrosol (50 µM pretreatment for 24 h each) showed
anti-angiogenesis activities as well(150). Indeed, all these com-
pounds suppressed angiogenesis in human umbilical vein
endothelial cells by inhibiting vascular endothelial growth factor
receptor 2 (VEGFR-2) signalling pathway. Specifically, HT and
taxifolin inhibited VEGF-dependent tyrosine phosphorylation of
VEGFR-2 by impairing phosphorylation of p42/p44 MAPK
(ERK1/2) and p46/p54 stress-activated protein kinase (SAPK)/
JNK(150). Altogether, these data provide further molecular
evidence of the beneficial effects of olive oil consumption in the
MedDiet in the treatment of metabolic diseases.
The soya isoflavones and their aglycones daidzein and gen-
istein, as well as the equol metabolite (40 µM for 2 h for each),
inhibited leptin secretion in mouse adipocytes(151). A mechan-
istic study carried out in 3T3-L1 adipocytes demonstrated that
genistein and daidzein inhibit TNFα-mediated down-regulation
of adiponectin through different mechanisms; genistein
inhibited TNFα-induced JNK signalling and daidzein inhibited
TNFα-induced down-regulation of FOXO1(152). Naringin (80 µM
pretreatment for 2 h) incubation down-regulated the high-
glucose-induced leptin expression and inhibited leptin-induced
activation of the p38 MAPK pathway in H9c2 cardiac cells(153).
An in vivo study showed that oral administration of naringin
(50mg/kg for 4 weeks) or hesperidin (50mg/kg for 4 weeks) in
diabetic rats significantly reduced the percentage of blood
glycated Hb, and serum levels of TNFα and IL-6(154). In humans,
purified anthocyanin (320mg/d for 12 weeks) supplementation
significantly increased serum adiponectin concentrations in
patients with T2D(146).
The metabolites of polyphenols can be useful biomarkers of
dietary intake to evaluate individual response to specific com-
pounds; for example, equol is not produced in all adults who
consume soya foods(155). A recent study has shown that, in pre-
diabetic and diabetic female population, the ‘equol producers’
subjects exhibited lower levels of leptin as compared with non-
producers, indicating an association between isoflavone intake
and leptin levels(155). In healthy obese postmenopausal women,
physical activity, diet and daily oral intake of a soya isoflavone
extract (60·8mg of genistein, 16mg of daidzein and 3·2mg of
glycitein) resulted in reduced levels of serum leptin and TNFα
associated with a significant increase in adiponectin, after
6 months of treatment(156).
A recent and exhaustive review describes the inhibitory
effects of certain polyphenols on TNFα-activated inflammatory
pathways both in vitro and in vivo, and in human studies(157).
The health effects of PUFA
A substantial amount of FA is required as additional source of
energy to support fetal cellular growth, and gestational hyper-
lipidaemia normally occurring during late pregnancy enhances
placental access to FA(158,159). GDM associates with an altered
maternal lipid profile and affects the quantity and/or quality of
lipids transferred to the fetus(160). In GDM, a positive correlation
between maternal TAG and NEFA levels, and fetal growth and
fat mass, has been found even in diabetic mothers with
appropriate glycaemic control(160). Fetus development depends
on the maternal supply of essential PUFA such as LA (18 : 2 n-6),
α-linolenic acid (ALA, 18 : 3 n-3) and long-chain (LC)-PUFA,
EPA (20 : 5 n-3), DHA (22 : 6 n-3) and arachidonic acid (AA,
20 : 4 n-6)(161). The placenta regulates adequate LC-PUFA
delivery to the fetus in a directional, preferential and timely
manner(161), preferentially transferring n-3 LC-PUFA(159). In
GDM women, the placental transfer of LC-PUFA appears to be
altered, with an impaired maternal-fetal transfer of DHA, which
might affect neurodevelopment programming in the
offspring(162). A reduced concentration of LC-PUFA in maternal,
placental and fetal compartments in GDM women compared
with healthy pregnant women has been highlighted(163,164).
However, increased, unchanged or lower hyperlipidaemia in
diabetic pregnant women v. non-diabetic pregnant women has
been observed too(160). In this regard, it has been hypothesised
that the degree of metabolic control and sex hormonal
dysfunction may influence the different degree of dyslipidaemia
observed in diabetic pregnant women(160). NEFA are taken up
by the placenta and FA are released from maternal lipoproteins
by endothelial lipase (EL) and lipoprotein lipase (LPL), which
are present in the maternal-facing microvillus membrane of the
syncytiotrophoblast(162). Increased EL mRNA has been found in
placenta from obese women with GDM compared with lean
GDM women or normoglycemic pregnant women(165). In
contrast, a recent study has shown that no difference in the
expression of LPL and EL exists between GDM and normogly-
caemic placentas, suggesting that these lipases are not involved
in the increased newborn adiposity(166). NEFA may enter the
cell by passive diffusion or by several plasma membrane-
located transport/binding proteins including FA translocase
(FAT/CD36), plasma membrane FABP(pm), FA transport pro-
teins (FATP1–6) and intracellular FABP(167). DHA and EPA are
endogenous ligands of several transcription factors such as
PPAR, RXR and SREBP1(168). A decreased expression of genes
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involved in FA uptake, intracellular transport, storage and
synthesis (e.g. LPL, FATP2, FATP6, FABPpm, acyl-CoA synthetase
long-chain family member 1), and of transcription factors involved
in lipid metabolism regulation (e.g. liver X receptor (LXRα),
PPARα, PPARδ, PPARγ, RXRα, SREBP1c), has been observed in
AT obtained from obese pregnant women and women with
GDM(109). These results indicate that pre-existing maternal obesity
and GDM are associated with abnormal AT lipid metabolism,
which may play a role in the pathogenesis of both diseases(109).
Dietary effects
PUFA are fundamental for human beings, and particularly
important is the balance of n-6:n-3 FA in maintaining homo-
eostasis, normal development and mental health throughout the
lifecycle(161). Different studies have led to the conclusion that
humans currently need a diet containing n-3 and n-6 PUFA in a
ratio of about 1:5; on the contrary, in Western diets, this ratio is
1:10–20, indicating a deficiency in n-3 FA and/or an excess of
n-6 FA(169). The essential FA, LA and ALA cannot be synthesised
by humans and therefore must be supplied through the diet; a
series of sequential desaturation and elongation reactions acting
in concert transform LA and ALA into their unsaturated deri-
vatives, namely AA from LA, EPA and DHA from ALA(170). EPA
and DHA are abundantly present in specific fishes, for example,
fresh tuna, salmon and mackerel, as well as in fish oil and
nuts(171,172). Nuts, vegetables, vegetable oils, for example,
soyabean, flaxseed and rapeseed oil, and cereals are also food
sources of ALA and LA(49,170). Walnuts are widely consumed in
Mediterranean regions and are rich in ALA (2·95 g/28·4 g)(173).
In the PREDIMED (PREvención con DIeta MEDiterránea) trial
that involved subjects at high risk for CVD, a diet rich in fats of
vegetable origin, olive oil and mixed nuts (30 g/d, as 15 g wal-
nuts, 7·5 g hazelnuts and 7·5 g almonds) has been shown to be
beneficial in the management of the metabolic syndrome(174).
The fat content of vegetables is low, but a high consumption of
vegetables will result in a substantial intake of ALA. The content
of ALA in some edible plants growing in the Mediterranean
regions is remarkable, as in the case with purslane (300–400mg
ALA/100 g)(175,176).
Different cohort studies have shown a positive association
between the adherence to MedDiet style, and plasma DHA and
EPA content, indicating that the MedDiet ensures higher n-3
PUFA bioavailability than Western diets(177–180).
The European Commission and the International Society for
the Study of Fatty Acids and Lipids specifically recommend that
pregnant and lactating women consume a minimum of 200mg
DHA/d(181). Several researches indicate that maternal dietary
supplementation with n-3 PUFA during pregnancy can reduce
the risk of pregnancy complications by limiting placental
inflammation and oxidative stress(159,182,183), with positive
action on insulin function, improvement of glucose tolerance
and lipid profiles(184,185) (Table 2).
A daily dose of 600mg of DHA, starting from the first trime-
ster until delivery, can ameliorate red cell membrane anomaly
in pregnant women with T2D and in neonates, and it prevents
the decline of maternal DHA during pregnancy(186). These
results suggest that DHA supplementation should be started in Ta
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the antenatal care of pregnant women with T2D. An Italian pilot
study revealed that daily administration of 200mg of DHA, from
the 8th week until delivery, reduced AA levels in erythrocytes
and plasma during gestational time(182). Thus, the increased
DHA levels in the maternal plasma and the consequent
reduction of AA-derived eicosanoids decrease inflammation,
with a beneficial effect on fetal development and growth, and
IR of amniochorial membranes as well(182). New identified
PUFA-derived mediators (specialised pro-resolving lipid med-
iators), namely resolvins, protectins, maresins and lipoxins, are
involved in inflammatory resolution(187). It has been observed
that maternal dietary supplementation with n-3 PUFA might
help placenta in resolving inflammation by increasing the levels
of these pro-resolving mediators, in rat(188) and in human
placenta(189). GDM women who received 1000mg/d n-3 FA
supplementation (containing 180mg of EPA and 120mg of
DHA) for 6 weeks, starting in weeks 24–28 of gestation, showed
a significant decrease in serum insulin levels and in HOMA
index (homoeostasis model of assessment–IR)(24), high-
sensitivity C-reactive protein (CRP) and better newborn out-
come(190), compared with placebo groups.
The need of higher PUFA intake in pregnancy is highlighted
by data collected from 600 women participating in the Alberta
Pregnancy Outcomes and Nutrition study(191). Through the
development of a dietary database for n-3 PUFA, the authors
evaluated PUFA intake each trimester of pregnancy and
3 months postpartum: results indicate that the majority of
women did not meet the European Union recommendation for
DHA during pregnancy(191).
The mechanism through which n-3 FA intake might influence
insulin metabolism is not well known. It has been hypothesised
that n-3 PUFA supplementation might affect insulin metabolism
and lipid profiles by activating AMPK(192). In agreement
with this finding, a recent study showed that RSV supple-
mentation, before, and throughout, pregnancy increased
placental DHA uptake capacity in pregnant non-human pri-
mates fed a high-fat diet (i.e. 36% fat supplemented with 0·37%
RSV)(193). This effect was associated with increased AMPK
activity and FATP-4, CD36 and FABPpm mRNA expression(193).
In addition, n-3 PUFA might modulate gene expression
through a variety of transcription factors with tissue-specific
effects; n-3 PUFA improve insulin metabolism by inhibiting
pro-inflammatory cytokine release and NF-κB protein
expression(194), and by activating their G-protein-coupled
receptor 120(195).
A recent meta-analysis showed that long-term supplementa-
tion of marine-derived n-3 PUFA results in a significant
reduction of IL-6, TNFα and CRP plasma levels, in both healthy
and non-healthy subjects(196).
Moreover, the increasing vegetarian and vegan population
requires alternative sources of LC-PUFA to guarantee them the
appropriate intake of n-3 FA(30,197,198). In addition to eating a
larger quantity of vegetables, with a higher content of essential
n-3 FA, a promising source of n-3 PUFA is represented by
different species of microalgae(199,200). To this purpose, the
European Commission has authorised the use in certain foods
of oil derived from microalgae Schizochytrium sp. rich in DHA
and EPA (EU decision no. 2015/545 and no. 2015/546),
Altogether, these data provide useful scientific information
for planning future investigations aimed at exploring PUFA
effects when considering a nutritional therapy of inflammatory
diseases and GDM.
Conclusions and future research
GDM is increasing worldwide; obesity worsens this condition
with increased risk of developing metabolic disorders in both
mother and offspring later in life. The adoption of healthy
lifestyle, with the adherence to a healthy dietary pattern, has
positive effects on the prevention and management of diabetes.
The Mediterranean diet is considered the model of healthy diet,
and even more studies demonstrate its power in reducing the
burden of several disorders in human being.
The few studies investigating the impact of healthy diet on
GDM indicate that adherence to a healthy dietary pattern before
pregnancy can reduce the risk of developing GDM; very few
data about the association between dietary exposure and GDM
outcomes are available.
Accordingly, this descriptive review tried to provide a picture
on what we know about the impact of specific dietary
biocompounds (i.e. polyphenols and PUFA) on the molecular
mechanisms involved in glucose homoeostasis. Literature data,
mostly derived from in vitro or animals studies, indicate that
almost all subclasses of flavonoids, as well as the stilbene RSV
and some olive oil phenolic compounds, interact and modulate
several molecular pathways regulating insulin sensitivity in
pancreatic β-cell, adipocyte, liver and muscle. Polyphenols
drive activation and/ or silencing of transcription factors and
consequently influence genes expression. Moreover, the fact
that miRNA are the target of polyphenols action is to be taken
into account in the future studies aimed at improving the
understanding of the biological effects of polyphenols.
However, how these compounds might work in GDM setting is
a matter of speculation. Although increasing data indicate the
beneficial effect of PUFA on pregnancy, a high-level evidence
has not yet been achieved to make recommendations for GDM.
Many gaps, in the nutritional field and in the knowledge of
pathophysiological processes, have to be filled in to progress in
GDM prevention and management. GDM results from a
complex interaction between the genetic background and
environment. Identifying a number of modifiable biomarkers
(including adipokines and miRNA) and the nutritional factors
(e.g. polyphenols and their metabolites) able to target them can
be useful in both early diagnosis and disease management.
It will be necessary to carry out dietary intervention studies
involving large cohorts, and take into account genetic and
dietary differences among races and countries. The ‘omics’
techniques will be fundamental tools to monitor dietary chan-
ges in populations and to identify the association between
dietary exposure and disease outcomes. The integration of data
from an individual’s genetic predisposition, endogenous meta-
bolome, food metabolome and mirRNome profiles by systems
biology approaches will provide a holistic view (systems biol-
ogy approaches) of the relations between diet and disease, and
will make it possible to translate these data in nutritional
recommendations and diseases management. In particular,
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differences in metabolic profiles will be useful to identify novel
biomarkers of dietary intake associated with disease. In this
regard, the recent creation of a database to estimate intake and
dietary seafood source of LC-PUFA in pregnancy provides a
useful tool and represents an important step for future inter-
vention studies.
Sharing this database along with others providing information
on dietary polyphenols and polyphenol metabolites will help
researchers to better understand the mechanisms governing
interaction between dietary active compounds and the human
organism.
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